Abrax­ane de­vel­op­er Igle­sias joins Sen­ti Bio­sciences; AB2Bio re­cruits CEO

→ Af­ter ac­cu­mu­lat­ing more than 30 years of bio­phar­ma ex­pe­ri­ence, Jose Igle­sias has been named CMO of Sen­ti Bio­sciences, a gene cir­cuit com­pa­ny based in the San Fran­cis­co area. Igle­sias is slat­ed to lead Sen­ti’s clin­i­cal de­vel­op­ment pro­grams with an em­pha­sis on treat­ing sol­id and liq­uid tu­mors. Igle­sias de­signed the can­cer drug Abrax­ane while he was at Abrax­is and Cel­gene, and his ex­ten­sive back­ground al­so in­cludes lead­er­ship po­si­tions at Eli Lil­ly, Apo­bi­ologix and Boston Bio­Med­ical.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.